Roxithromycin inhibits the effector phase of delayed-type hypersensitivity

Area of Science:

• Immunology
• Pharmacology

Background:

• Delayed-type hypersensitivity (DTH) and contact hypersensitivity (CHS) are T-cell mediated immune responses.
• Understanding modulators of these hypersensitivity reactions is crucial for developing new therapeutic strategies.

Purpose of the Study:

• To investigate the immunomodulatory effects of roxithromycin on DTH and CHS in vivo.
• To determine the impact of roxithromycin administration timing on hypersensitivity responses.

Main Methods:

• Sheep red blood cell (SRBC)-induced DTH and 2,4,6-Trinitrochlorobenzene (TNCB)-induced CHS models in mice.
• Assessment of ear swelling, matrix metalloproteinase-9 (MMP-9) activity, splenocyte proliferation, cytokine gene expression (IL-2, IFN-gamma), and T-cell survival.

Main Results:

• Roxithromycin significantly suppressed SRBC-induced DTH and TNCB-induced CHS when administered during the effector phase, but not the induction phase.
• Administration in the effector phase down-regulated MMP-9 activity, inhibited T-helper type 1 (Th1) cytokine gene expression, and decreased concanavalin A (Con A)-induced splenocyte proliferation.
• No inhibitory effect on CHS was observed with continuous treatment in a multi-challenge model.

Conclusions:

• Roxithromycin exhibits immunomodulatory effects, primarily when administered during the effector phase of hypersensitivity reactions.
• The drug appears to alleviate DTH by suppressing effector T-cell function and survival, potentially through down-regulation of MMP-9 and Th1 cytokines.